Research programme: allergy therapy - Infinity Pharmaceuticals/Kyorin
Alternative Names: Allergy therapy research programme - Infinity Pharmaceuticals/KyorinLatest Information Update: 07 Dec 2007
At a glance
- Originator Infinity Pharmaceuticals; Kyorin Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypersensitivity
Most Recent Events
- 26 Sep 2006 No development reported - Preclinical for Allergy in USA (unspecified route)
- 13 Sep 2006 Discovery Partners International has been acquired and merged into Infinity Pharmaceuticals
- 09 Sep 2003 Preclinical trials in Allergy in USA (unspecified route)